New drug aims to lower dangerous fats in the blood

NCT ID NCT03747224

Completed Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new medicine called ARO-ANG3 in 93 people, including healthy volunteers and patients with high cholesterol or high triglycerides. The main goal was to check if the drug is safe and how the body processes it. This research helps determine if the drug should be tested in larger studies for managing lipid disorders.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias familial hypercholesterolemia hyperlipidemia Hyperlipoproteinemia Type II hypertriglyceridemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIAS FAMILIAL HYPERCHOLESTEROLEMIA HYPERTRIGLYCERIDEMIA

Contacts and locations

Show contact details

Locations

Research Site 1

Nedlands, 6009, Australia
Research Site 2

Camperdown, New South Wales, 2050, Australia
Research Site 3

Adelaide, South Australia, 5000, Australia
Research Site 4

Grafton, Auckland, 1010, New Zealand
Research Site 5

Papatoetoe, Aukland, 2025, New Zealand
Research Site 6

Christchurch, 8011, New Zealand